Helixgate https://validator.w3.org/feed/docs/rss2.html The future of RAS inhibitors FDA delays approval decision for Exelixis’ tyrosine kinase inhibitor in colorectal cancer Singapore launches biotech-focused Boston hub to build on ‘centuries-old bond’ After FDA nod for novel Cabometyx formulation, analysts predict limited threat to Exelixis Fierce Pharma Asia—Takeda’s R&D leadership change; Daiichi’s $1.3B court win; New Samsung Bio contract CDMO Argonaut sheds life sciences, diagnostics division for undisclosed sum In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy ABEC to expand global manufacturing network with new Wilson facility Exegenesis Bio and Modalis sign research deal for Duchenne therapy FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system Eco-NAMs Webinar Series | QSARs to Predict Aquatic Toxicity – 09/17/2026 Advancing Generic Drug Development: Modernizing Bioequivalence Approaches for Topical & Transdermal Products – 09/10/2026 FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy Notable Approvals | Drugs Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing – 09/14/2026 NLS Days 2026: what’s dealmaking like in the Nordics? Selective oestrogen receptor degrader class grows with new cancer approval Samsung Biologics inks $262M manufacturing deal with European pharma company Encoded raises $275m for Dravet therapy and other financings UK review recommends ‘L plates’ for new healthcare AIs AbbVie charts a new course for CGRPs in menstrual migraine Hengrui gets world-first okay for platelet drug hetrombopag Synthetic biology Moderna flu vaccine wins FDA approval FDA approves oncolytic virus Cancer Treatment Genetic Effects in Healthy Cells May Reveal Clues to Side Effects and Resistance Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving Mice Bone Marrow-on-a-Chip Model Offers New Window Into Immune Cell Development and Behavior Epidural Kit Correction: Medical Action Industries Issues Correction for Epidural Kits Containing Spectra Medical Devices Lidocaine Ampules Home Biotech’s 2026 IPOs deliver broad gains through August Novartis DM1 miss raises stakes for next wave of DMPK readouts Novel Drug Approvals for 2026 Rare Disease Drug Approvals What’s New Related to Drugs Disc sets up polycythemia vera challenge but Silence maintains lead Drugs@FDA Data Files FDA places partial hold on Biohaven’s epilepsy drug mRNA cancer vaccines’ biggest barriers to market Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more STAT+: Cancer medicines remain in short supply across the U.S., survey finds Preclinical Pulse: The research catching our eye in September 2026 Rewriting the rules of genetic medicine with tRNA therapeutics TwoStep Therapeutics secures $62.5m funding to advance TS-104 Solstice Oncology secures $225m to drive porustobart’s development for cancer For PDUFA VIII, the most valuable incentive may be time August biopharma layoffs impact just over 500, down 90% year over year